[go: up one dir, main page]

UY25800A1 - Procedimiento para preparar composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina. - Google Patents

Procedimiento para preparar composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina.

Info

Publication number
UY25800A1
UY25800A1 UY25800A UY25800A UY25800A1 UY 25800 A1 UY25800 A1 UY 25800A1 UY 25800 A UY25800 A UY 25800A UY 25800 A UY25800 A UY 25800A UY 25800 A1 UY25800 A1 UY 25800A1
Authority
UY
Uruguay
Prior art keywords
insulin sensitizer
pharmaceutical composition
modified release
procedure
composition including
Prior art date
Application number
UY25800A
Other languages
English (en)
Inventor
Re Vincenzo
Skinner Janet Louise
Sauer Joseph
Muldoon William
Milosovich Susan Marie
Glinecke Robert
Original Assignee
Smithkline Beecham P L C Y Smi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9824870.1A external-priority patent/GB9824870D0/en
Priority claimed from GBGB9912189.9A external-priority patent/GB9912189D0/en
Application filed by Smithkline Beecham P L C Y Smi filed Critical Smithkline Beecham P L C Y Smi
Publication of UY25800A1 publication Critical patent/UY25800A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un procedimiento para preparar una composición farmacéutica, que comprende formular el sensibilizador de insulina tiazolidinadiónico y el vehículo farmacéuticamente aceptable de modo que permita una liberación modificada del sensibilizador de insulina. Dicha composición es útil en el tratamiento de la diabetes mellitus de tipo 2.
UY25800A 1998-11-12 1999-11-15 Procedimiento para preparar composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina. UY25800A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9824870.1A GB9824870D0 (en) 1998-11-12 1998-11-12 Novel composition and use
GBGB9912189.9A GB9912189D0 (en) 1999-05-25 1999-05-25 Novel composition and use

Publications (1)

Publication Number Publication Date
UY25800A1 true UY25800A1 (es) 2000-08-21

Family

ID=26314667

Family Applications (2)

Application Number Title Priority Date Filing Date
UY25798A UY25798A1 (es) 1998-11-12 1999-11-12 Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico.
UY25800A UY25800A1 (es) 1998-11-12 1999-11-15 Procedimiento para preparar composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY25798A UY25798A1 (es) 1998-11-12 1999-11-12 Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico.

Country Status (39)

Country Link
EP (3) EP1917962A1 (es)
JP (1) JP2002529505A (es)
KR (2) KR20060097140A (es)
CN (1) CN1289081C (es)
AP (2) AP2008004490A0 (es)
AR (2) AR023700A1 (es)
AT (1) ATE382352T1 (es)
AU (1) AU768578B2 (es)
BG (2) BG109893A (es)
BR (1) BR9915215A (es)
CA (1) CA2350659C (es)
CO (1) CO5190673A1 (es)
CY (1) CY1107909T1 (es)
CZ (1) CZ20011628A3 (es)
DE (1) DE69937898T2 (es)
DK (1) DK1128827T3 (es)
DZ (1) DZ2937A1 (es)
EA (3) EA200702648A1 (es)
EG (2) EG24463A (es)
ES (1) ES2299269T3 (es)
HK (1) HK1040909B (es)
HR (2) HRP20080117A2 (es)
HU (1) HUP0104307A3 (es)
ID (1) ID29344A (es)
IL (2) IL143003A0 (es)
MY (1) MY135973A (es)
NO (1) NO20012351L (es)
NZ (2) NZ511611A (es)
OA (1) OA11676A (es)
PE (1) PE20001428A1 (es)
PL (1) PL198717B1 (es)
PT (1) PT1128827E (es)
RS (1) RS50208B (es)
SI (1) SI1128827T1 (es)
SK (1) SK286937B6 (es)
TR (2) TR200101337T2 (es)
TW (2) TWI257305B (es)
UY (2) UY25798A1 (es)
WO (1) WO2000028990A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
EP1244468A2 (en) * 2000-01-07 2002-10-02 University Of Cincinnati Selective activation of a th1 or th2 lymphocyte regulated immune response
CA2403670C (en) * 2001-01-31 2010-02-09 Rohm Gmbh & Co. Kg Multiparticulate drug form comprising at least two differently coated pellet forms
DE60209824T2 (de) * 2001-12-21 2006-10-19 Smithkline Beecham Corp. Dosierschema für ppar-gamma-aktivatoren
MY139719A (en) * 2002-02-12 2009-10-30 Glaxo Group Ltd Oral dosage form for controlled drug release
CN100367960C (zh) * 2002-07-11 2008-02-13 武田药品工业株式会社 包衣制剂的制备方法
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
EP1589951B1 (en) * 2003-01-03 2017-08-09 Supernus Pharmaceuticals, Inc. Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
MXPA05007883A (es) 2003-01-29 2005-09-21 Takeda Pharmaceutical Proceso para producir una preparacion recubierta.
ES2241478B1 (es) * 2004-02-13 2006-11-16 Lacer S.A. Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo.
FI20060501L (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
EP2731593A4 (en) * 2011-07-14 2015-07-01 Able Cerebral Llc COMPOSITION, DEVICE AND METHOD FOR DELAYED AND PROLONGED DELIVERY OF ENERGY MOLECULES TO THE BRAIN
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group P.L.C., Brentford Substituierte Thiazolidindionderivate
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US5061717A (en) 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
MX15171A (es) 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
KR930701436A (ko) 1990-07-03 1993-06-11 오노다 마사아이 비스헤테로환 화합물
CA2087437A1 (en) 1990-08-23 1992-02-24 Steven W. Goldstein Hypoglycemic hydroxyurea derivatives
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
KR100249988B1 (ko) 1991-04-11 2000-04-01 로렌스 티. 마이젠헬더 티아졸리딘디온 유도체, 그의 제조방법 및 용도
US5502078A (en) * 1991-05-28 1996-03-26 Zeneca Limited Chemical compounds
TW222626B (es) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
WO1993021166A1 (en) 1992-04-10 1993-10-28 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type ii-diabetes
WO1993022445A1 (en) 1992-05-05 1993-11-11 The Upjohn Company A process for producing pioglitazone metabolite
WO1994001420A1 (en) 1992-07-03 1994-01-20 Smithkline Beecham Plc Heterocyclic compounds as pharmaceutical
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
JP3256841B2 (ja) * 1996-06-27 2002-02-18 武田薬品工業株式会社 ベンズアルデヒド化合物の製造法
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
WO1998042340A1 (en) * 1997-03-24 1998-10-01 Galderma Research & Development, S.N.C. Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus

Also Published As

Publication number Publication date
AP1901A (en) 2008-10-24
CA2350659A1 (en) 2000-05-25
EA200100540A1 (ru) 2001-10-22
ID29344A (id) 2001-08-23
PT1128827E (pt) 2008-03-10
EA200601144A1 (ru) 2007-02-27
BR9915215A (pt) 2001-07-31
CY1107909T1 (el) 2013-09-04
PE20001428A1 (es) 2001-02-08
EP1128827B1 (en) 2008-01-02
EG24463A (en) 2009-07-16
HRP20010342A2 (en) 2002-06-30
NO20012351D0 (no) 2001-05-11
ES2299269T3 (es) 2008-05-16
EA200702648A1 (ru) 2008-10-30
HRP20080117A2 (en) 2008-10-31
HRP20010342B1 (en) 2008-04-30
TR200101337T2 (tr) 2001-11-21
TWI246920B (en) 2006-01-11
MY135973A (en) 2008-07-31
BG65444B1 (bg) 2008-08-29
CN1289081C (zh) 2006-12-13
EP1815855A1 (en) 2007-08-08
AU1272900A (en) 2000-06-05
AP2008004490A0 (en) 2008-06-30
BG105570A (en) 2002-02-28
CO5190673A1 (es) 2002-08-29
PL198717B1 (pl) 2008-07-31
CN1333683A (zh) 2002-01-30
RS50208B (sr) 2009-07-15
EP1917962A1 (en) 2008-05-07
HK1040909A1 (en) 2002-06-28
ATE382352T1 (de) 2008-01-15
CZ20011628A3 (cs) 2001-12-12
SK6432001A3 (en) 2001-12-03
BG109893A (bg) 2008-11-28
DE69937898T2 (de) 2009-01-02
IL183972A0 (en) 2007-10-31
NO20012351L (no) 2001-07-04
TWI257305B (en) 2006-07-01
EG22344A (en) 2002-12-31
DK1128827T3 (da) 2008-04-28
TW200505436A (en) 2005-02-16
KR20010073229A (ko) 2001-07-31
DE69937898D1 (de) 2008-02-14
EP1128827A1 (en) 2001-09-05
HK1040909B (en) 2008-08-01
JP2002529505A (ja) 2002-09-10
HUP0104307A3 (en) 2003-12-29
KR20060097140A (ko) 2006-09-13
TR200503846T2 (tr) 2007-01-22
HUP0104307A2 (hu) 2002-07-29
DZ2937A1 (fr) 2004-03-15
NZ526440A (en) 2005-01-28
AR023699A1 (es) 2002-09-04
PL348153A1 (en) 2002-05-06
AR023700A1 (es) 2002-09-04
CA2350659C (en) 2009-06-09
NZ511611A (en) 2003-10-31
EA007608B1 (ru) 2006-12-29
SK286937B6 (sk) 2009-07-06
OA11676A (en) 2005-01-12
SI1128827T1 (sl) 2008-06-30
AU768578B2 (en) 2003-12-18
WO2000028990A1 (en) 2000-05-25
YU36401A (sh) 2004-05-12
IL143003A0 (en) 2002-04-21
UY25798A1 (es) 2000-12-29
KR100732599B1 (ko) 2007-06-27

Similar Documents

Publication Publication Date Title
UY25800A1 (es) Procedimiento para preparar composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina.
UY25799A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina y otro agente antidiabético.
AR017979A1 (es) Formulaciones farmaceuticas de epotilonas, metodo para su preparacion y el uso de los mismos para la manufactura de un medicamento
ES2160577T3 (es) Nuevos esteres de aminoalcoholes biciclicos y triciclicos, su preparacion y su utilizacion en medicamentos.
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
AR025959A1 (es) DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
CO5280073A1 (es) Composiciones
ES2170813T3 (es) Acidos 2,2-dicloroalcanocarboxilicos, proceso para su preparacion, medicamentos que los contienen y su uso para tratar la resistencia a la insulina.
CL2009001899A1 (es) Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
AR127064A1 (es) Prodroga de derivados de pirrolidona como activador de glucoquinasa
KR910007867A (ko) 페네타놀아민 화합물
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
CO4940454A1 (es) Nuevo metodo de tratamiento
AR016350A1 (es) Uso de un sensibilizador a insulina, un secretagogo de insulina y un agente antihiperglucemico inhibidor de alfa-glucosidasa para prepararmedicamentos
UY25103A1 (es) Composición para el tratamiento de diabetes mellitus
AR013352A1 (es) Uso de un sensibilizador a insulina y un agente antihiperglucemico para la preparacion de un medicamento para el tratamiento de la diabetes mellitus ycondiciones asociadas a la misma y una composicion farmaceutica.
AR012996A1 (es) Uso de un sensibilizador a la insulina para la preparacion de un medicamento y composicion farmaceutica que comprende dicho sensibilizador.
UY25801A1 (es) Procedimiento para preparar composiciones para el tratamiento de diabetes.
AR028699A1 (es) Nueva formulacion
WO2001047509A3 (en) Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
ECSP993216A (es) Nueva composicion y uso ii
ECSP982593A (es) Nuevo metodo de tratamiento vi
AP1692A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.
AR010343A1 (es) Uso de 17 beta-dihidroequilenina o una sal farmaceuticamente aceptable del ester de 17 beta-dihidroequilenina-3-sulfato para la manufactura de unmedicamento como antioxidante y composicion farmaceutica.

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20090302